The Lancet  
Jan 19, 2013  Volume 381  Number 9862  p177 – 266  e1
http://www.thelancet.com/journals/lancet/issue/current

Comment
More evidence for use of pneumococcal conjugate vaccines
Cynthia G Whitney

Preview
Pneumococcal conjugate vaccines (PCVs) are among the leading interventions for reducing deaths and improving the health of children around the world. These vaccines are now routinely used in about 88 countries, with the number of countries increasing quickly.1 PCVs are used on various schedules, designed to complement existing schedules for other vaccines that are already part of national immunisation programmes. Until now, however, clinical trial evidence to support some of the different ways PCVs can be used was missing.

Articles
Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial
Arto A Palmu, Jukka Jokinen, Dorota Borys, Heta Nieminen, Esa Ruokokoski, Lotta Siira, Taneli Puumalainen, Patricia Lommel, Marjan Hezareh, Marta Moreira, Lode Schuerman, Terhi M Kilpi
Preview | Summary